Skip to content
Heart icon (animated) heart icon (static)
Share
Download Report

Selected Pharmaceuticals in Development as of January 24, 2023

Cardiovascular and Metabolism

aprocitentan

Difficult to treat hypertension
Registration

AAV-RPGR

Retinitis Pigmentosa
Phase 3

AAV-CNGB3

Achromatopsia
Phase 2

Milvexian (Factor Xla)

Prevention and Treatment of Thrombosis
Phase 2

JNJ-7100

Diabetic Macular Oedema
Phase 1

AAV-CNGA3

Achromatopsia
Phase 1

JNJ-0237

Autosomal Dominant Polycystic Kidney Disease
Phase 1

JNJ-1887​

Macular Degeneration
Phase 1

JNJ-0795

Non-Alcoholic Steatohepatitis
Phase 1

Infectious Diseases and Vaccines, Global Public Health

CABENUVA

HIV Adolescents
Registration

VAC52150

Monovalent Ebola Virus Vaccine
Registration

VAC31518

Janssen COVID-19 Vaccine
Registration

VAC18193

RSV Adult Vaccine
Phase 3

REMICADE (Infliximab)

COVID-19
Phase 3

VAC89220

HIV Px Vaccine
Phase 3

VAC52416

Multivalent ExPEC Vaccine
Phase 3

JNJ-0953

Influenza
Phase 2

JNJ-3989

Hepatitis B/D Co-infection
Phase 2

JNJ-3989 Combination Therapy

Hepatitis B
Phase 2

JNJ-1802

Dengue Prophylaxis
Phase 2

Ultra Long-Acting

HIV
Phase 1

JNJ-7744

Hepatitis B
Phase 1

JNJ-3283 Combination Therapy

Hepatitis B
Phase 1

Immunology

STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis
Registration

TREMFYA (guselkumab)

Subcutaneous Induction (ASTRO)
Phase 3

TREMFYA (guselkumab)

Crohn's Disease Subcutaneous Induction
Phase 3

TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage
Phase 3

TREMFYA (guselkumab)

Ulcerative Colitis Monotherapy
Phase 3

TREMFYA (guselkumab)

Pediatric Psoriasis
Phase 3

TREMFYA (guselkumab)

Crohn's Disease
Phase 3

STELARA (ustekinumab)

Pediatric Ulcerative Colitis
Phase 3

STELARA (ustekinumab)

Pediatric Crohn's Disease
Phase 3

SIMPONI (golimumab)

Pediatric Ulcerative Colitis
Phase 3

nipocalimab​

Warm Autoimmune Hemolytic Anemia
Phase 3

TREMFYA (guselkumab)

Giant Cell Arteritis
Phase 2

nipocalimab​

Idiopathic inflammatory myopathy
Phase 2

nipocalimab​

Hemolytic disease of the fetus and newborn
Phase 2

nipocalimab​

Sjogren's Syndrome
Phase 2

nipocalimab​

Systemic lupus erythematosus
Phase 2

nipocalimab​

Rheumatoid Arthritis
Phase 2

bermekimab

Hidradenitis Suppurativa
Phase 2

JNJ-4804 Combination Therapy

Crohn's Disease
Phase 2

JNJ-4804 Combination Therapy

Psoriatic Arthritis
Phase 2

JNJ-4804 Combination Therapy

Ulcerative Colitis
Phase 2

JNJ-2113

Psoriasis
Phase 2

JNJ-1459

Psoriasis
Phase 1

JNJ-9280

Inflammatory Bowel Disease
Phase 1

JNJ-4703

Rheumatoid Arthritis
Phase 1

Neuroscience

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms
Phase 3

nipocalimab​

Chronic Inflammatory Demyelinating Polyneuropathy
Phase 3

nipocalimab​

Generalized Myasthenia Gravis
Phase 3

aticaprant

Adjunctive Major Depressive Disorder
Phase 3

seltorexant

Probable Alzheimer's with clinically significant agitation/aggression
Phase 2

nipocalimab​

Generalized Myasthenia Gravis Pediatrics
Phase 2

SPRAVATO (esketamine)

Major Depressive Disorder with Suicidal Ideation Pediatrics
Phase 2

anti-phospho-tau mAb

Alzheimer's Disease
Phase 2

P2X7 antagonist

Bipolar Disease
Phase 2

JNJ-1813

Epilepsy
Phase 2

VAC20121 *

Alzheimer's Disease
Phase 1

small molecule MGLLi

Psychiatric Disorders
Phase 1

JNJ-0376

Parkinson's Disease
Phase 1

Oncology

niraparib

L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone
Registration

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)
Registration

IMBRUVICA (ibrutinib)

Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)
Registration

BALVERSA (erdafitinib)

Urothelial cancer
Registration

ERLEADA (apalutamide)

Tablet Reduction
Registration

talquetamab (GPRC5D/CD3)

Relapsed Refractory Multiple Myeloma
Registration

teclistamab (BCMA/CD3)

Relapsed Refractory multiple myeloma
Registration

niraparib / abiraterone acetate

M1 Metastatic Castration-Sensitive Prostate Cancer in combination with abiraterone acetate and Prednisone
Phase 3

amivantamab / lazertinib

Non Small Cell Lung Cancer
Phase 3

IMBRUVICA Ibrutinib

Relapsed Refractory Mantle Cell Lymphoma (VEGA)
Phase 3

IMBRUVICA (ibrutinib)

Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)
Phase 3

IMBRUVICA (ibrutinib)

Relapsed Refractory patients with Indolant Non-Hodgkins Lymphoma (SELENE)
Phase 3

TAR-200 (RIS/gemcitabine plus cetrelimab)

Muscle invasive bladder cancer
Phase 3

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible (PERSEUS)
Phase 3

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)
Phase 3

DARZALEX (daratumumab)

Smoldering multiple myeloma (SMM3001)
Phase 3

ERLEADA (apalutamide)

High risk prostate cancer (PROTEUS)
Phase 3

ERLEADA (apalutamide)

Localized prostate cancer
Phase 3

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI
Phase 3

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed Refractory multiple myeloma w/1-3 PL
Phase 3

talquetamab (GPRC5D/CD3)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)
Phase 3

teclistamab

TE NDMM maintenance (MajesTEC-4)
Phase 3

teclistamab (BCMA/CD3)

Multiple Myeloma 1-3PLs
Phase 3

RYBREVANT (amivantamab)

Subcutaneous (PALOMA-3)
Phase 3

amivantamab / lazertinib

Non Small Cell Lung Cancer 2L
Phase 3

RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy
Phase 3

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non muscle invasive bladder cancer
Phase 2

BALVERSA (erdafitinib)

Non muscle invasive bladder cancer
Phase 2

BALVERSA (erdafitinib)

Tumor Agnostic
Phase 2

JNJ-8343

Prostate Cancer
Phase 1

VAC85135

Hematological Malignancies
Phase 1

erdafitinib

Intravesical Delivery System for Localized Bladder Cancer
Phase 1

JNJ-8543

Hematological Malignancies
Phase 1

JNJ-8114

Prostate Cancer
Phase 1

JNJ-5322

Multiple Myeloma
Phase 1

JNJ-8780

Hematological Malignancies
Phase 1

JNJ-6617

Hematological Malignancies
Phase 1

JNJ-9414

Prostate Cancer
Phase 1

JNJ-6420

Prostate Cancer
Phase 1

JNJ-6633

Hematological Malignancies
Phase 1

JNJ-4681

Hematological Malignancies
Phase 1

JNJ-1330

Colorectal Cancer
Phase 1

Pulmonary Hypertension

UPTRAVI (selexipag)

Pediatric pulmonary arterial hypertension
Phase 3

macitentan

Pulmonary arterial hypertension 75mg
Phase 3

macitentan

Chronic thromboembolic pulmonary hypertension 75mg
Phase 3

OPSUMIT (macitentan)

Pediatric pulmonary arterial hypertension
Phase 3

macitentan w/tadalafil FDC

Pulmonary arterial hypertension
Phase 3

prostacyclin receptor agonist

Pulmonary Arterial Hypertension
Phase 1
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; aprocitentan: Idorsia; X-Linked Retinitis Pigmentosa (AAV-RPGR) and Achromatopsia Gene Therapies (CNGA3 and CNGB3): MeiraGTx; JNJ-7100: Exonate; JNJ-1887: Hemera Biosciences; PNPLA3: Arrowhead Pharmaceuticals; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; COVID-19 vaccine: funded in part with federal funds from the U.S. Department of Health and Human Services; JNJ-3989: Arrowhead Pharmaceuticals; bacteriophage products using recombinant CRISPR/Cas3 Phage platform: Locus Biosciences; Cloudbreak antiviral conjugates (AVCs) including CD388: Cidara Therapeutics; Janssen's HIV vaccine program: IPCAVD, MHRP, HJF, the Ragon Institute, IAVI, Bill & Melinda Gates Foundation, NIAID, U.S. Military HIV Research Program, U.S. Army Medical Materiel Development Activity, MIT, Harvard, HVTN, SAMRC, Bavarian Nordic; Zika vaccine: Beth Israel Deaconess Medical Center (Harvard Medical School); ExPEC: GSK; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113, JNJ-4238 and JNJ-5186: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sload Kettering; cilta-cel: Legend Biotech; niraparib: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); Janssen's Monovalent Ebola Vaccine: Bavarian Nordic A/S, NIAID, IMI2, EFPIA, BARDA, NIH; Filovirus multivalent vaccine: Bavarian Nordic
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue